BioStem Technologies, Inc. (OTC: BSEM), a MedTech company specializing in perinatal tissue-derived products for advanced wound care, announced that company management will present at the 46th Annual TD Cowen Healthcare Conference in Boston, Massachusetts. The presentation is scheduled for Monday, March 2, 2026, at 3:50 pm ET. This conference appearance provides BioStem with a platform to discuss its innovations in regenerative medicine before an audience of healthcare investors and industry professionals.
The company focuses on developing, manufacturing, and commercializing allografts using its proprietary BioRetain® processing method. This method is designed to maintain growth factors and preserve tissue structure, leveraging the latest research in regenerative medicine. BioStem's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks (AATB) and comply with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). These credentials underscore the company's commitment to high standards in tissue banking and product safety, which is critical for regulatory approval and patient trust in medical applications.
BioStem's product portfolio includes brands such as VENDAJE®, VENDAJE AC®, American Amnion™, American Amnion AC™, and the Neox® and Clarix® product lines. These products are used in advanced wound care and regenerative therapies, addressing conditions that require tissue repair and healing. The presentation at the TD Cowen conference may highlight clinical outcomes or market expansions related to these products, potentially impacting investor perceptions and stock performance. Interested parties can access live and archived webcasts of the presentation on the investors section of the company's website at https://ir.biostemtechnologies.com.
This announcement matters because it positions BioStem within a competitive MedTech landscape, where visibility at major conferences can drive investment and partnerships. The regenerative medicine market is growing, fueled by an aging population and increasing prevalence of chronic wounds, with global demand for advanced therapies. BioStem's focus on perinatal tissue—a rich source of biological materials—offers potential advantages in healing and regeneration, which could translate into broader healthcare impacts if scaled effectively. The company's adherence to AATB accreditation and cGTP/cGMP standards may also set benchmarks for quality in the industry, influencing safety protocols and product development across similar firms.
For more information on BioStem Technologies, visit https://biostemtechnologies.com. The latest news and updates relating to the company are available in its newsroom at https://tinyurl.com/bsemnewsroom.
